The role of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: A basis for primary prevention in Guinea-Conakry, West Africa

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue SUPPL. 4, 2002, Pages

  Turner, Paul C ^a   Sylla, Abdoulaye ^b   Diallo, Mamadou S ^b   Castegnaro, Jean Jacques ^c   Hall, Andrew J ^c   Wild, Christopher P ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b Inst de Rech Biol Appl de Guinee   (Guinea)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Aflatoxin; Biomarkers; Carcinogen adducts; Hepatitis B virus; Hepatocellular carcinoma; Liver; Molecular epidemiology

Indexed keywords

AFLATOXIN; ALUMINOSILICATE CALCIUM; CARCINOGEN; CHLOROPHYLL; DNA; ENZYME; HEPATITIS VACCINE; OLTIPRAZ;

CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENDEMIC DISEASE; ENZYME ACTIVITY; EPIDEMIC; HEPATITIS; HEPATITIS B VIRUS; HEPATITIS VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER INJURY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; TRANSGENIC MOUSE;

EID: 12244286810     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.17.s4.7.x     Document Type: Review

References (73)

1. Pisani P, Parkin DM, Munoz N, Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomarkers Prev. 1997; 6: 387-400.
2. Montesano R, Wild CP. Chemical-viral interactions in carcinogenesis. In: Iversen OH ed. New Frontiers in Cancer Causation: Proceedings of the Second International Conference on Theories of Carcinogenesis. Washington: Taylor & Francis. 1993; 283-99.
3. International Agency for Research on Cancer. IARC Monographs on the evaluation of carcinogenic risks to humans. Hepatitus viruses. Vol. 59. IARC, Lyon, 1994.
4. International Agency for Research on Cancer. IARC Monograph on the evaluation of carcinogenic risks to humans. Some naturally occurring substances: Food items and constituents, heterocyclic aromatic amines and mycotoxins. Vol. 56, IARC, Lyon, 1994.
5. Parkin DM. The global burden of cancer. Semin. Cancer Biol. 1998; 8: 219-35.
6. Jelinek CF, Pohland AE, Wood GE. Worldwide occurrence of mycotoxins in foods and feeds - an update. J. Assoc. Off. Anal. Chem. 1989; 72: 223-30.
7. Beardall J, Miller JD. Natural occurrence of mycotoxins other than aflatoxin in Africa, Asia and South America. Mycotoxin Res. 1994; 10: 21-40.
8. CAST. Mycotoxins: economic and health risks. Council for Agricultural Sciences and Technology, Ames, USA 1989.
9. Turner PC, Nikiema P, Wild CP. Fumonisin contamination of food: progress in development of biomarkers to better assess human health risks. Mutation Res. 1999; 443: 81-93.
10. Montesano R, Hainaut P, Wild CP. Hepatocellular carcinoma: from gene to public health. J. Natl Cancer Inst. 1997; 89: 1844-51.
11. Sylla A, Diallo MS, Castegnaro J, Wild CP. Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma; a molecular epidemiological approach. Mutation Res. 1999; 428: 187-96.
12. Wild CP, Hall AJ. Hepatitis B virus and liver cancer: Unanswered questions. Cancer Surveys 1999; 33: 35-54.
13. Wild CP, Hall AJ. Primary prevention of hepatocellular carcinoma in developing countries. Mutat. Res. 2000; 462: 381-393.
14. qian GS, Ross RK, Yu MC, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol. Biomarkers Prev. 1994; 3: 3-10.
15. Wang LY, Hatch M, Chen CJ, et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int. J. Cancer 1996; 67: 620-5.
16. Wild CP, Kleihues P. Etiology of cancer in humans and animals. Exp Toxicologic Pathol. 1996; 48: 95-100.
17. Sell S, Hunt JM, Dunsford HA, Chisari FV. Synergy between hepatitis B virus expression and chemical hepatocarcinogens in transgenic mice. Cancer Res. 1991; 51: 1278-85.
18. Feitelson MA, Duan LX. Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am. J. Pathol. 1997; 150: 1141-57.
19. 1 in the development of murine liver cancer. Int. J. Oncol. 1995; 7: 735-40.
20. Slagle BL, Lee TH, Medina D, Finegold MJ, Butel JS. Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. Mol. Carcinog. 1996; 15: 261-9.
21. Chisari FV. Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepatology 1995; 22: 1316-25.
22. Bannasch P, Khoshkhou NI, Hacker HJ, et al. Synergistic hepatocarcinogenic effect of hepadnaviral infection and dietary aflatoxin B1 in woodchucks. Cancer Res. 1995; 55: 3318-30.
23. Cullen JM, Marion PL, Sherman GJ, Hong X, Newbold JE. Hepatic neoplasms in aflatoxin B1-treated, congenital duck hepatitis B virus-infected, and virus-free Pekin ducks. Cancer Res. 1990; 50: 4072-80.
24. Cova L, Wild CP, Mehrotra R, et al. Contribution of aflatoxin B1 and hepatitis B virus infection in the induction of liver tumours in ducks. Cancer Res. 1990; 50: 2156-63.
25. Uchida T, Suzuki K, Esumi M, Arii M, Shikata T. Influence of aflatoxin B1 intoxication on duck livers with duck hepatitis B virus infection. Cancer Res. 1988; 48: 1559-65.
26. Dunsford HA, Sell S, Chisari FV. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis-B virus transgenic mice. Cancer Res. 1990; 50: 3400-7.
27. Duflot A, Mehrotra R, Yu SZ, Barraud L, Trepo C, Cova L. Spectrum of liver disease and duck hepatitis B virus infection in a large series of Chinese ducks with hepatocellular carcinoma. Hepatology 1995; 21: 1483-91.
28. Yan Rq, Su JJ, Huang DR, Gan YC,Yang C, Huang GH. Human hepatitis B virus and hepatocellular carcinoma. II. Experimental induction of hepatocellular carcinoma in tree shrews exposed to hepatitis B virus and aflatoxin B1. J. Cancer Res. Clin. Oncol. 1996; 122: 289-95.
29. Harris CC, Sun TT. Interactive effects of chemical carcinogens and hepatitis B virus in the pathogenesis of hepatocellular carcinoma. Cancer Surv. 1986; 5: 765-80.
30. Wild CP, Jansen LA, Cova L, Montesano R. Molecular dosimetry of aflatoxin exposure: contribution to understanding the multifactorial etiopathogenesis of primary hepatocellular carcinoma with particular reference to hepatitis B virus. Environ. Health Perspect. 1993; 99: 115-22.
31. Chemin I, Takahashi S, Belloc C, et al. Differential induction of carcinogen metabolizing enzymes in a transgenic mouse model of fulminant-hepatitis. Hepatology 1996; 24: 649-56.
32. Kirby GM, Chemin I, Montesano R, Chisari FV, Lang MA, Wild CP. Induction of specific cytochrome P450s involved in aflatoxin B1 metabolism in hepatitis B virus transgenic mice. Mol. Carcinog. 1994; 11: 74-80.
33. Chomarat P, Rice JM, Slagle BL, Wild CP. Hepatitis B virus-induced liver injury and altered expression of carcinogen metabolising enzymes: the role of the HBx protein. Toxicol. Lett. 1998; 102-103: 595-601.
34. Chemin I, Ohgaki H, Chisari FV, Wild CP. Altered expression of hepatic carcinogen metabolizing enzymes with liver injury in HBV transgenic mouse lineages expressing various amounts of hepatitis B surface antigen. Liver 1999; 19: 81-7.
35. Chomarat P, Sipowicz MA, Diwan BA, et al. Distinct time courses of increase in cytochromes P450 1a2, 2a5 and glutathione S-transferases during the progressive hepatitis associated with Helicobacter Hepaticus. Carcinogenesis 1997; 18: 2179-90.
36. Kirby GM, Pelkonen P, Vatanasapt V, Camus AM, Wild CP, Lang MA. Association of liver fluke (Opisthorchis viverrini) infestation with increased expression of cytochrome P450 and carcinogen metabolism in male hamster liver. Mol. Carcinog. 1994; 11: 81-9.
37. Zhou T, Evans AA, London WT, et al. Glutathione S-transferase expression in hepatitis B virus-associated human hepatocellular carcinogenesis. Cancer Res. 1997; 57: 2749-53.
38. Wild CP, Fen Y, Turner PC, et al. Environmental and genetic determinants of aflatoxin-albumin adducts in The Gambia. Int. J. Cancer 2000; 86: 1-7.
39. Allen SJ, Wild CP, Wheeler JG, et al. Aflatoxin exposure malaria and hepatitis B infection in rural Gambian children. Trans. R. Soc. Trop. Med. Hyg. 1992; 86: 426-30.
40. Wild CP, Fortuin M, Donato F, et al. Aflatoxin, liver enzymes, and hepatitis B virus infection in Gambian children. Cancer Epidemiol. Biomarkers Prev. 1993; 2: 555-61.
41. Turner PC, Mendy M, Whittle H, Fortuin M, Hall AJ, Wild CP. Hepatitis B infection and aflatoxin biomarker levels in Gambian children. Trop Med Intl Health, 5: 837-41.
42. Fortuin M, Chotard J, Jack AD, et al. Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation. Lancet 1993; 341: 1129-31.
43. Hall AJ, Inskip HM, Loik F, Chotard J, Jawara M, Vall Mayans M. Hepatitis B vaccine in the expanded programme of immunisation: The Gambian Experience. Lancet 1989; Vol. 1: 11057-9.
44. Hall AJ, Roberton RL, Crivelli PE, Lowe Y, Inskip HM, Snow SK, Whittle H. Cost-Effectiveness of Hepatitis B Vaccine in the Gambia. Trans. R. Soc. Trop Med. Hyg. 1993; 87: 333-6.
45. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N. Engl. J. Med. 1997; 336: 1855-9.
46. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995; 13 (Suppl. 1): S47-9.
47. IPCS World Health Organization. Food additives Series 40, Safety evaluation of certain food additives and contaminants. Aflatoxins. Geneva: IPCS, WHO 2000: 361-468.
48. D'Mello JPF, Macdonald AMC, Postel D, Dijksma WTP, Dujardin A, Placinta CM. Pesticide use and mycotoxin production in Fusarium and Apergillus phytopathogens. Euro. J. Plant Pathol. 1998; 104: 741-51.
49. Cotty PJ, Bayman P, Egel DS, et al. Agriculture, Aflatoxins and Aspergillus. In: Powell KA, et al. ed. The Genus Aspergillus. New York: Plenum Press, 1994; 1-27.
50. Bhatnagar D, Cotty PJ, Cleveland TE. Food Flavor and Safety. American Chemical Society; 1993, 22, Prehavest Aflatoxin Contamination Molecular Strategies for its control. 272-92.
51. Dorner JW, Cole RJ, Wicklow DT. Aflatoxin reduction in corn through field application of competitive fungi. J. Food Prot. 1999; 62: 650-6.
52. Wambugu F.Why Africa needs agricultural biotech. Nature 1999; 400: 15-6.
53. Bhatnagar D, Cleveland TE, Cotty PJ. Mycological aspects of aflatoxin formation. In: Eaton DL, Groopman JD, eds. The Toxicology of Aflatoxins: Human Health, Veterinary and Agricultural Significance. Eaton: Academic Press, 1994; 327-46.
54. Bhatnagar D, Cleveland T, Linz J, Payne G. Molecular biology to eliminate aflatoxins. INFORM 1995; 6: 262-71.
55. Payne GA. Aflatoxin in maize. Critic Rev. Plant Sci. 1992; 10: 423-40.
56. Keenan JI, Savage GP. Mycotoxins in groundnuts, with special reference to aflatoxin. In: Smartt J, ed. The Ground-nut Crop: a Scientific Basis for Improvement. London: Chapman & Hall; 1994; 509-51.
57. Compton JAF, Tyler PS, Hindmarsh PS, Golob P, Boxall RA, Haines CP. Reducing losses in small farm grain storage in the tropics Trop. Sci. 1993; 33: 283-318.
58. Karlovsky P. Biological detoxification of fungal toxins and its use in plant breeding, feed and food production. Nat. Toxins 1999; 7: 1-23.
59. Phillips TD, Clement BA, Park DL. Approaches to reduction of aflatoxins in foods and feeds. In: Eaton DA, Groopman JW. eds. The Toxicology of Aflatoxins. Human Health Veterinary and Agricultural Significance. Academic Press Inc. San Diego 1994; 18: 383-406.
60. Dickens Whitaker TB. Efficacy of electronic color sorting and hand picking to remove aflatoxin contaminated kernels from contaminated lots of shelled peanuts. Peanut Sci. 1975; 2: 45-50.
61. Shantha T, Sreenivasa M, Rati ER, Prema V. Detoxifica-tion of groundnut seeds by urea and sunlight. J. Food Safety 1986; 7: 225-32.
62. Njapau H, Muzungaile EM, Changa RC. The effect of village processing techniques on the content of aflatoxins in corn and peanuts in Zambia. J. Sci. Food Agri. 1998; 76: 450-6.
63. Yu SZ. Primary prevention of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 1995; 10: 674-82.
64. Kensler TW, Groopmam JD, Sutter TR, Curphey TJ, Roebuck BD. Development of cancer chemopreventive agents: Oltipraz as a paradigm. Chem. Res. Toxicol. 1999; 12: 113-26.
65. Wang JS, Shen X, He X, et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of qidong, People's Republic of China. J. Natl Cancer Inst. 1999; 91: 347-54.
66. Kensler TW, He X, Otieno M, et al. Oltipraz chemoprevention trial in qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol. Biomarkers Prev. 1998; 7: 127-34.
67. Wang JS, qian GS, Zarba A, et al. Temporal patterns of aflatoxin-albumin adducts in hepatitis B surface antigen-positive and antigen-negative residents of Daxin, qidong County, People's Republic of China. Cancer Epidemiol. Biomarkers Prev. 1996; 5: 253-61.
68. Chi WJ, Doong SL, Lin-Shiau SY, Boone CW, Kelloff GJ, Lin JK. Oltipraz, a novel inhibitor of hepatitis B virus transcription through elevation of p53 protein. Carcinogenesis 1998; 19: 2133-8.
69. Abdel-Wahhab MA, Nada SA, Amra HA. Effect of aluminosilicates and bentonite on aflatoxin-induced developmental toxicity in rat. J. Appl. Toxicol. 1999; 19: 199-204.
70. Dashwood R, Negishi T, Hayatsu H, Breinholt V, Hendricks J, Bailey G. Chemopreventive properties of chlorophylls towards aflatoxin B1: a review of the antimutagenicity and anticarcinogenicity data in rainbow trout. Mutat. Res. 1998; 399: 245-53.
71. Koulibaly M, Kabba IS, Cisse A, et al. Cancer incidence in Conakry, Guinea: first results from the cancer registry 1992-95. Int. J. Cancer 1997; 70: 39-45.
72. Diallo MS, Sylla A, Sidibe K, Sylla BS, Trepo CR, Wild CP. Prevalence of exposure to aflatoxin and hepatitis B and C viruses in Guinea, West Africa. Nat. Toxins 1995; 3: 6-9.
73. Chapot B, Wild CP. ELISA for quantification of aflatoxin-albumin adducts and their application to human exposure assessment. In: Chapot B, Wild CP. Warhol M, van Velzen D, Bullock GR, eds. Techniques in Diagnostic Pathology. Vol. II San Diego: Academic Press, 1991; 135-55.